National Pension Service Grows Holdings in Boston Scientific Corporation $BSX

National Pension Service increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 8.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,761,615 shares of the medical equipment provider’s stock after buying an additional 296,409 shares during the period. National Pension Service owned about 0.25% of Boston Scientific worth $358,670,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. Egerton Capital UK LLP increased its stake in Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after buying an additional 3,671,548 shares during the period. Alphinity Investment Management Pty Ltd acquired a new position in Boston Scientific during the 4th quarter worth $252,918,000. Marshall Wace LLP grew its holdings in Boston Scientific by 30.7% during the 3rd quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after acquiring an additional 2,301,383 shares in the last quarter. Credit Agricole S A acquired a new position in Boston Scientific during the 3rd quarter worth $204,812,000. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Boston Scientific by 28.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 8,367,398 shares of the medical equipment provider’s stock worth $816,909,000 after acquiring an additional 1,837,480 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 2.7%

NYSE BSX opened at $49.12 on Friday. Boston Scientific Corporation has a one year low of $48.41 and a one year high of $109.50. The company has a 50-day simple moving average of $60.69 and a 200-day simple moving average of $78.84. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm has a market capitalization of $73.01 billion, a PE ratio of 20.55, a price-to-earnings-growth ratio of 0.93 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the business posted $0.75 EPS. The company’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.37 earnings per share for the current year.

Boston Scientific declared that its board has initiated a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific advanced several clinical programs, including updates on its FARAPULSE pulsed-field ablation study and a diabetic neuropathy trial that is nearing a key data milestone, which could support future product growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: Unusual options activity showed heavy call buying in BSX, suggesting some traders are positioning for a rebound.
• Neutral Sentiment: Wall Street brokerage consensus still leans bullish overall, with the stock holding a “Moderate Buy” rating from analysts.
• Neutral Sentiment: Boston Scientific continues to work on its device pipeline and capital deployment strategy, which may help offset current franchise weakness over time. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight from Overweight, citing uncertainty around the EP business and the WATCHMAN franchise. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Management’s reduced 2026 organic growth outlook and comments about slower WATCHMAN procedures and competitive pressure in electrophysiology were the main catalysts behind the stock’s decline. Boston Scientific shares fall 10% on Watchman weakness, competitive pressures

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Evercore decreased their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. JPMorgan Chase & Co. decreased their price objective on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Jefferies Financial Group decreased their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Argus raised shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $77.00 price objective on shares of Boston Scientific in a report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $87.46.

Insider Activity

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig purchased 3,580 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 9,800 shares of company stock valued at $554,012. Company insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.